Covered recipient · General Payments record
KATELYN CARMICAL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2024
$1,993.72
- Reported across 135 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $504.81 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $194.21 | 14 |
| PFIZER INC. | $64.24 | 4 |
| GlaxoSmithKline, LLC. | $42.06 | 3 |
| Astellas Pharma US Inc | $41.04 | 2 |
| Amgen Inc. | $40.82 | 2 |
| Novo Nordisk AS | $29.71 | 2 |
| Otsuka America Pharmaceutical, Inc. | $17.59 | 1 |
| DEXCOM, INC. | $16.74 | 1 |
| Acerta Pharma LLC | $16.37 | 1 |
| Merck Sharp & Dohme Corporation | $15.01 | 1 |
| Lilly USA, LLC | $13.59 | 1 |
| Exact Sciences Corporation | $13.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.46 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417873 | CMS |
| ABBVIE INC. | $12.14 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417875 | CMS |
| ABBVIE INC. | $5.18 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417877 | CMS |
| ABBVIE INC. | $18.84 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417879 | CMS |
| ABBVIE INC. | $33.08 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417881 | CMS |
| ABBVIE INC. | $13.19 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417883 | CMS |
| ABBVIE INC. | $18.68 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417885 | CMS |
| ABBVIE INC. | $0.51 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417887 | CMS |
| ABBVIE INC. | $12.74 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417889 | CMS |
| ABBVIE INC. | $14.78 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417891 | CMS |
| ABBVIE INC. | $14.21 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417893 | CMS |
| ABBVIE INC. | $23.07 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417895 | CMS |
| ABBVIE INC. | $2.21 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417897 | CMS |
| ABBVIE INC. | $8.12 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103417899 | CMS |
| Amgen Inc. | $19.82 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117218126 | CMS |
| Amgen Inc. | $21.00 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117218128 | CMS |
| Astellas Pharma US Inc | $21.82 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139336596 | CMS |
| Astellas Pharma US Inc | $19.22 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139268554 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.37 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105572737 | CMS |
| Dexcom, Inc. | $16.74 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153313087 | CMS |
| Exact Sciences Corporation | $13.43 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114607871 | CMS |
| GlaxoSmithKline, LLC. | $13.91 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116401937 | CMS |
| GlaxoSmithKline, LLC. | $13.89 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116426147 | CMS |
| GlaxoSmithKline, LLC. | $14.26 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116485975 | CMS |
| Lilly USA, LLC | $13.59 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135092229 | CMS |
| Merck Sharp & Dohme LLC | $15.01 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141979901 | CMS |
| Novo Nordisk Inc | $13.78 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096670564 | CMS |
| Novo Nordisk Inc | $15.93 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096907891 | CMS |
| Otsuka America Pharmaceutical, Inc. | $17.59 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118871676 | CMS |
| PFIZER INC. | $14.95 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131120923 | CMS |
| PFIZER INC. | $14.95 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131324672 | CMS |
| PFIZER INC. | $17.97 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131386538 | CMS |
| PFIZER INC. | $16.37 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131138744 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.